Relmada
Relmada Acquires Promising Tourette’s Syndrome Drug Candidate from Asarina Pharma
Relmada Therapeutics, Asarina Pharma, Sepranolone, Tourette’s syndrome, neurosteroid, Phase 2b, asset acquisition, CNS disorders
Relmada Therapeutics Explores Strategic Alternatives Following Discontinuation of Two Phase 3 Trials
Relmada Therapeutics, Phase 3 trials, Strategic alternatives, REL-1017, REL-P11, Central nervous system diseases, Metabolic disorders
Relmada Therapeutics Considers Strategic Alternatives Following Depression Drug Setbacks
Relmada Therapeutics, depression drug, REL-1017, strategic alternatives, sale, major depressive disorder, NMDA receptor blocker
Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017
Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development